

## Osteoporosis: risk assessment, treatment and prevention of fragility fractures Committee meeting 12

**Date:** 23/09/2024

**Location:** Virtual (Zoom)

**Minutes:** Final

Committee members present:		
Alison Tedstone (Chair)		(Present for notes 1 – 6)
Nicola Peel (Topic adviser)		(Present for notes 1 – 6)
Alison Ahmed		(Present for notes 1 – 6)
Sherwin Criseno		(Present for notes 1 – 6)
Elaine Dennison		(Present for notes 4 – 6)
Paul Hamilton		(Present for notes 1 – 6)
Karen Knapp		(Present for notes 1 – 6)
Iain Macleod		(Present for notes 1 – 6)
Nicholas Pipkin		(Present for notes 1 – 6)
Stuart Ralston		(Present for notes 1 – 6)
Rajesh Varma		(Present for notes 1 – 6)
Karen Whitehead		(Present for notes 1 – 6)

In attendance:		
Annette Chalker	Technical Analyst	(Present for notes 1 – 6)
Linyun Fun	Technical Analyst	(Present for notes 1 – 6)
Amber Hernaman	Project Manager	(Present for notes 1 – 6)
Bernard Higgins	Clinical Advisor	(Present for notes 1 – 6)
Clare Jones	Senior Technical Analyst	(Present for notes 1 – 6)
Maria Majeed	Technical Analyst	(Present for notes 1 – 6)
Qudsia Malik	Senior Technical Analyst	(Present for notes 1 – 6)
Lisa Miles	Technical Analyst	(Present for notes 1 – 6)
Suzie Panek	Resource Impact	(Present for notes 1 – 6)
Eric Power	Deputy Director (Centre for Guidelines)	(Present for note 5)
Muksitur Rahman	Health Economist	(Present for notes 1 – 6)
Carlos Sharpin	Guideline Lead	(Present for notes 1 – 6)

Daniel Smithson	Technical Analyst	(Present for notes 1 – 6)
Alison Wray	Technical Analyst	(Present for notes 1 – 6)

### Apologies:

Irene Baker	Committee Member
Kay Morgan	Committee Member
Rachel Muir	Committee Member
Kate Lovibond	Senior Health Economist
Rebecca Boucher	Content Editor
Sarah Glover	Information Specialist

## 1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 12<sup>th</sup> Osteoporosis guideline committee.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included.

- Monitoring for people not on treatment but at risk of fragility fracture
- Calcium and vitamin D
- Patient information
- An update on the pharmacological treatment review

## 2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was monitoring for people not on treatment but at risk of fragility fracture and calcium and vitamin D.

The Chair asked everyone to verbally declare any interests that had arisen since the last meeting.

Name	Affiliation	Declarations of Interest, date declared	Type of interest	Decision taken
Alison Tedstone	Chair	I was interviewed for the paper on the Scientific Advisory Committee on Nutrition <a href="https://www.bmj.com/content/386/bmj.q1909">https://www.bmj.com/content/386/bmj.q1909</a>  I am quoted several times and appear in a	Financial interest	Declare and participate

		<p>video embedded in paper BMJ website.</p> <p>The paper is about potential conflicts of interest of committee members, specific to nutrition.</p> <p>It has no direct relevance to NICE</p>		
<b>3. Minutes of last meeting</b>				
Agreed.				
<b>4. Evidence reviews</b>				
<p>Linyun Fou updated the committee and led on the discussion of clinical evidence for monitoring for people not on treatment but at risk of fragility fracture and then made live edits to the recommendations.</p> <p>Annette Chalker and Muksitur Rahman presented the clinical evidence and the economics evidence to the committee. Carlos Sharpin then made live edits to the recommendations.</p> <p>Carlos Sharpin led on the discussion of patient information and made live edits to the recommendations.</p>				
<b>5. Pharmacological treatment update</b>				
Eric Power (Deputy Director for the Centre for Guidelines at NICE) attended for this section of the meeting to update the committee on the pharmacological review and Technology Appraisal incorporation.				
<b>6. AOB</b>				
Karen Whitehead raised if this guideline would cover pregnancy associated osteoporosis. Carlos Sharpin will discuss with the internal team at NICE and report back.				

**Date of next meeting:** 30/10/2024

**Location of next meeting:** Zoom